Posted by Michael Wonder on 17 Jun 2024
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
17 June 2024 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Efficacy was evaluated in KEYNOTE-868/NRG-GY018, a multi-centre, randomised, double-blind, placebo-controlled trial enrolling 810 patients with advanced or recurrent endometrial carcinoma.
